Ionis Pharma (NASDAQ: IONS) reported second quarter EPS of $0.70, $0.94 better than the analyst estimate of $-0.24. Revenue for the quarter came in at $452M versus the consensus estimate of $286.01M.
Guidance
Ionis Pharma sees FY 2025 revenue of $825.00M-$850.00M versus the analyst consensus of $755.80M.
Ionis Pharma’s stock price closed at $41.48. It is up 26.54% in the last 3 months and down -16.13% in the last 12 months.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.